Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion

Objective: The prognosis of intrahepatic vascular invasion, including unilateral or main portal vein tumor thrombosis (PVTT) and hepatic vein thrombosis, is still poor. Many patients with intrahepatic vascular invasions never receive radiotherapy (RT). In recent years, more conformal RT techniques s...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan-Chen Lo, Feng-Chun Hsu, Shih-Kai Hung, Kuo-Chih Tseng, Yu-His Hsieh, Moon-Sing Lee, Chih-Wei Tseng, Hon-Yi Lin, Liang-Cheng Chen, Wen-Yen Chiou
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Tzu Chi Medical Journal
Subjects:
Online Access:http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2019;volume=31;issue=1;spage=40;epage=46;aulast=Lo
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849315937314930688
author Yuan-Chen Lo
Feng-Chun Hsu
Shih-Kai Hung
Kuo-Chih Tseng
Yu-His Hsieh
Moon-Sing Lee
Chih-Wei Tseng
Hon-Yi Lin
Liang-Cheng Chen
Wen-Yen Chiou
author_facet Yuan-Chen Lo
Feng-Chun Hsu
Shih-Kai Hung
Kuo-Chih Tseng
Yu-His Hsieh
Moon-Sing Lee
Chih-Wei Tseng
Hon-Yi Lin
Liang-Cheng Chen
Wen-Yen Chiou
author_sort Yuan-Chen Lo
collection DOAJ
description Objective: The prognosis of intrahepatic vascular invasion, including unilateral or main portal vein tumor thrombosis (PVTT) and hepatic vein thrombosis, is still poor. Many patients with intrahepatic vascular invasions never receive radiotherapy (RT). In recent years, more conformal RT techniques such as intensity-modulated RT (IMRT) have been developed and applied to treat other cancers and have significantly improved treatment results and decreased side effects. The purpose of this study is to evaluate the treatment results in patients with intrahepatic vascular invasion and explore the role of IMRT in these treatments. Materials and Methods: There were a total of 73 patients with newly diagnosed AJCC stage IIIB hepatocellular carcinoma (HCC), with either PVTT or hepatic vein tumor thrombosis between 2007 and 2015 in our hospital. IMRT was used for all patients who received RT. Prognostic factors, including treatment modalities, liver function, and comorbidities, were analyzed using univariate and multivariate analysis with the Cox model. Survival time was analyzed using the Kaplan–Meier method. Results: The longest follow-up time was 45.3 months. The median age was 67 years. Univariate analyses indicated that IMRT, transarterial chemoembolization (TACE), target therapy (sorafenib), tumor size, Child-Pugh class, and ascites were significantly associated with overall survival (OS). In multivariate analysis, IMRT (hazard ratio [HR], 0.495; P = 0.019), sorafenib (HR, 0.340; P = 0.013), tumor size (HR, 2.085; P = 0.020), and Child-Pugh class (P = 0.004), were independent prognostic predictors for patients with intrahepatic vessel invasion, but TACE and ascites were not. The outcomes of patients who had different treatment modalities were significantly different (P < 0.001). Patients who received IMRT with TACE had the best outcomes. Patients who received an RT dose above 5400 cGy had better outcomes than those who with a dose below 5400 cGy, although the results were not significantly different (P = 0.248). Conclusion: IMRT is an important treatment component for patients with intrahepatic vascular invasion. Combined treatment modalities, such as IMRT with TACE, could improve the outcomes of HCC patients with intrahepatic vessel invasion.
format Article
id doaj-art-e3354c74bf1843e892af0f0b1bedcc7b
institution Kabale University
issn 1016-3190
2223-8956
language English
publishDate 2019-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Tzu Chi Medical Journal
spelling doaj-art-e3354c74bf1843e892af0f0b1bedcc7b2025-08-20T03:52:00ZengWolters Kluwer Medknow PublicationsTzu Chi Medical Journal1016-31902223-89562019-01-01311404610.4103/tcmj.tcmj_14_18Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasionYuan-Chen LoFeng-Chun HsuShih-Kai HungKuo-Chih TsengYu-His HsiehMoon-Sing LeeChih-Wei TsengHon-Yi LinLiang-Cheng ChenWen-Yen ChiouObjective: The prognosis of intrahepatic vascular invasion, including unilateral or main portal vein tumor thrombosis (PVTT) and hepatic vein thrombosis, is still poor. Many patients with intrahepatic vascular invasions never receive radiotherapy (RT). In recent years, more conformal RT techniques such as intensity-modulated RT (IMRT) have been developed and applied to treat other cancers and have significantly improved treatment results and decreased side effects. The purpose of this study is to evaluate the treatment results in patients with intrahepatic vascular invasion and explore the role of IMRT in these treatments. Materials and Methods: There were a total of 73 patients with newly diagnosed AJCC stage IIIB hepatocellular carcinoma (HCC), with either PVTT or hepatic vein tumor thrombosis between 2007 and 2015 in our hospital. IMRT was used for all patients who received RT. Prognostic factors, including treatment modalities, liver function, and comorbidities, were analyzed using univariate and multivariate analysis with the Cox model. Survival time was analyzed using the Kaplan–Meier method. Results: The longest follow-up time was 45.3 months. The median age was 67 years. Univariate analyses indicated that IMRT, transarterial chemoembolization (TACE), target therapy (sorafenib), tumor size, Child-Pugh class, and ascites were significantly associated with overall survival (OS). In multivariate analysis, IMRT (hazard ratio [HR], 0.495; P = 0.019), sorafenib (HR, 0.340; P = 0.013), tumor size (HR, 2.085; P = 0.020), and Child-Pugh class (P = 0.004), were independent prognostic predictors for patients with intrahepatic vessel invasion, but TACE and ascites were not. The outcomes of patients who had different treatment modalities were significantly different (P < 0.001). Patients who received IMRT with TACE had the best outcomes. Patients who received an RT dose above 5400 cGy had better outcomes than those who with a dose below 5400 cGy, although the results were not significantly different (P = 0.248). Conclusion: IMRT is an important treatment component for patients with intrahepatic vascular invasion. Combined treatment modalities, such as IMRT with TACE, could improve the outcomes of HCC patients with intrahepatic vessel invasion.http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2019;volume=31;issue=1;spage=40;epage=46;aulast=LoHepatic vein thrombosisHepatocellular carcinomaPortal vein thrombosisPrognosticatorsRadiotherapyTransarterial chemoembolization
spellingShingle Yuan-Chen Lo
Feng-Chun Hsu
Shih-Kai Hung
Kuo-Chih Tseng
Yu-His Hsieh
Moon-Sing Lee
Chih-Wei Tseng
Hon-Yi Lin
Liang-Cheng Chen
Wen-Yen Chiou
Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
Tzu Chi Medical Journal
Hepatic vein thrombosis
Hepatocellular carcinoma
Portal vein thrombosis
Prognosticators
Radiotherapy
Transarterial chemoembolization
title Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
title_full Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
title_fullStr Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
title_full_unstemmed Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
title_short Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
title_sort prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
topic Hepatic vein thrombosis
Hepatocellular carcinoma
Portal vein thrombosis
Prognosticators
Radiotherapy
Transarterial chemoembolization
url http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2019;volume=31;issue=1;spage=40;epage=46;aulast=Lo
work_keys_str_mv AT yuanchenlo prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT fengchunhsu prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT shihkaihung prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT kuochihtseng prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT yuhishsieh prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT moonsinglee prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT chihweitseng prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT honyilin prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT liangchengchen prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion
AT wenyenchiou prognosticatorsofhepatocellularcarcinomawithintrahepaticvascularinvasion